This Botox Competitor Is on the Rise
Allergan Plc, the battered drugmaker whose stock has lost a third of its value in under five months, fell as much as 4.1 percent Tuesday to the lowest since late 2013 after a small-cap biotech competitor revealed data for what’s been touted as a “better Botox.”
Photographer: Jason Alden/Bloomberg
This article is for subscribers only.
Allergan Plc, the battered drugmaker whose stock has lost a third of its value in under five months, fell as much as 4.1 percent Tuesday to the lowest since late 2013 after a small-cap biotech competitor revealed data for what’s been touted as a “better Botox.”
The latest threat to Allergan’s best-selling product is an experimental therapy from Revance Therapeutics Inc. known as RT002. The new drug appeared to last longer than Botox when used to smooth wrinkles between the eyebrows in late-stage studies. Revance plans to file an application with U.S. regulators in the first half of 2019 and could introduce the drug in 2020 if it’s approved.